Volume 9 Supplement 1 July 2019

TALKS 13 Intracellular ion channels and transporters 15 RNA processing Table of Contents 16 Signal transduction PLENARY LECTURES 17 Mitochondria and signaling 18 DNA architecture Saturday 6 July 19 RNA transcription 3 Opening Plenary Lecture Monday 8 July Sunday 7 July 20 DNA editing and modification 3 IUBMB Lecture 22 RNA transport and translation 3 The FEBS Journal Richard Perham Prize Lecture 24 Single cell analysis and imaging 3 FEBS/EMBO Women in Science Award Lecture 25 Calcium and ROS signaling Monday 8 July 26 Sulfur metabolism and cellular regulation 27 Molecular neurobiology 4 FEBS Datta Lecture 29 RNA turnover 4 FEBS Sir Hans Krebs Lecture 30 Cytoskeleton and molecular mechanisms of motility Tuesday 9 July 31 Rare diseases 4 FEBS Theodor Bücher Lecture Tuesday 9 July 5 FEBS 2019 Plenary Lecture 32 Signaling in brain cancer Wednesday 10 July 34 Synthetic biopolymers for biomedicine 5 PABMB Lecture 35 Integrative approaches to structural and synthetic biology 5 EMBO Lecture 37 Induced pluripotent cells Thursday 11 July 39 Long noncoding RNA 40 Neurodegeneration 5 Closing Plenary Lecture 42 Cell therapy and regenerative medicine FEBS SPECIAL SESSIONS 44 Small noncoding RNA Sunday 7 July Wednesday 10 July 6 Gender issues in science 45 Proteins: structure, disorder and dynamics 47 Plant biotechnology Monday 8 July 48 Natural networks and systems 6 Education 1 – Creative teaching: effective learning in life sciences 50 RNA in pathogenesis and therapy education 51 Biochemistry, a success story Tuesday 9 July 52 Molecular biology of aging 7 Education 2 – Future education now! 53 Plant–environment interaction 7 Science and Society – Personalised medicine: a future vision 54 Synthetic networks and systems 55 Multicomponent complexes Wednesday 10 July Thursday 11 July 8 Research and career skills 57 Cell signaling in tumor biology SYMPOSIA 59 Bionanotechnology Sunday 7 July 60 Epigenetics and protein glycosylation 9 Molecular mechanism of inflammation-related diseases 61 Genome editing (CRISPR) 10 DNA variation 62 Proteomic technologies 12 Cardiovascular diseases

Abstracts submitted to the 44th FEBS Congress, taking place in Krakow, Poland from 6th to 11th July 2019, and accepted by the Congress Organizing Committee are published in this Supplement of FEBS Open Bio. Late-breaking abstracts are not included in this issue.

About these abstracts Abstracts submitted to the Congress are not peer-reviewed. In addition, abstracts are published as submitted and are not copyedited prior to publication. We are unable to make corrections of any kind to the abstracts once they are published.

Indexing Abstracts published in FEBS Open Bio Supplement for the 44th FEBS Congress will be included individually in the Conference Proceedings Citation Index published by Web of Science.

How to cite these abstracts AuthorOne, A., AuthorTwo, B. (2019). Abstract title. FEBS Open Bio, 9: Abstract number*. doi:10.1002/2211-5463.12674

* The Abstract number begins with the letters PL, SS, S or ShT and can be found atop each abstract’s title in the PDF file.

FEBS Open Bio 9 (Suppl.1) (2019) 2–64 DOI: 10.1002/2211-5463.12674 2 © 2019 The Authors. FEBS Open Bio © 2019 FEBS

FFEB4_v9_s1_12674.inddEB4_v9_s1_12674.indd 1 66/18/2019/18/2019 9:46:559:46:55 AMAM SYMPOSIA Thursday 11 July differential processing of proenkephalinergic and proopiome- ShT-39-1 lanocortin (POMC) systems among controls, prolactin-secreting Semi-targeted metabolomic studies of microadenomas, and non-secreting macroadenomas. We will pre- methamphetamine’s biotransformations and sent our discovery data on growth hormone (GH) isoforms, dif- ferentially expressed proteins (n = 56) between controls and its impact on macrophage’s secreted macroadenomas, novel phosphoproteins, and oxidative stress metabolome nitroproteins (NS). All of these data profoundly impact on our K. Pawlak1, K. Lech2, A. Vei3, A. Harwood3, P. Ciborowski3 knowledge of human neuroendocrinology. 1Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland, 2Faculty of Chemistry, Warsaw University of Technology, Warszawa, Poland, 3Department of Pharmacology S-39-3 and Experimental Neuroscience, University of Nebraska Medical Omics in precision medicine Center (UNMC), Omaha, United States of America J. Bergquist Methamphetamine (MA) is an illegal psychostimulant. Despite Analytical Chemistry and Neurochemistry, Department of the prevalence of MA addiction, its effect on the innate immune Chemistry – Biomedical Centre, Uppsala University, Uppsala, system is not known. Several reports showed the effect of MA on Sweden various aspects of intracellular signaling, yet changes in intracel- It has been estimated that only Alzheimer’s disease (AD) alone, lular and secreted metabolomes induced by MA in human mono- the most common form of dementia, will affect approximately 81 cyte derived macrophages (hMDM) has been understudied. In million individuals by 2040. To date, the actual cause and cascade this study, we used a semi-targeted metabolomic approach to of events in the progression of many neurological and neurodegen- investigate the effect of MA on macrophages secreted metabo- erative diseases have not been fully determined. Furthermore, there lism. Culture supernatants from hMDM exposed to MA or con- is no definitive blood test or simple diagnostic method for many trols were subjected to solid phase extraction (SPE, Plexa PCX) of those diseases so far available. Fibril formation of proteins, or liquid-liquid extraction and followed by reversed phase chro- together with a dysfunctional regulation of lipids and steroids, has matography performed with two columns connected in-line (EC been shown to play a fundamental role influencing various risk 50/2 Nucleodur C18 Pyramid, 3 lm and EC 150/2.1 Cogent, factors of neurodegeneration and pathogenesis. Recently, there has UDC-Cholesterol, 4 lm). A QTRAP 6500 MS/MS System with a been a stronger focus on proteomics and metabolomics (e.g. lipi- Turbo Spray ion source (SCIEX, Framingham, MA, USA) work- domic) studies with the hope of increasing our understanding of ing in multiple reaction monitoring mode (MRM) was used as a the underlying mechanisms leading to disease. Technological detection system. Selected MRM list was based on research advancements in high-resolution mass spectrometry and rapid papers, databases (e.g. HMDB, METLIN). During analytical improvements in chromatographic techniques have led to quick work-flow, identity verification was found as the most critical expansion of the field of in this research. In this presentation, step. It was performed using enhanced product ion mode (EPI) emphasis is given to the new developments in technologies and supported by a chemical characteristic of analytes (RPLC – their applications in disease biomarker discovery. polarity and SPE – acid-base properties). Results presented in this paper describe three novel aspects of metabolomic research. First, we present an attempt to analyze the metabolic secretome S-39-2 of hMDM exposed to Meth in comparison to non-exposed con- Large-scale label-free clinical proteomics and trol cells. We measured 94 metabolites and identified 11 that were phosphoproteomics for precision medicine significantly different between control and Meth-exposed macro- C. Jimenez phages. Our new analytical approach, utilizing combined C18 OncoProteomics Laboratory, Department of Medical Oncology, and Cogent columns, allowed us to separate and identify OHMA VUmc-Cancer Center Amsterdam, Amsterdam, the Netherlands, isomers. Lastly, we have found two presumably unknown Amsterdam, Netherlands metabolites pending structural determination and confirmation. This work is supported by R01 DA043258 and P30 MH062261 The general goal of our clinical cancer proteomics efforts is to grants from National Institutes of Health (USA). disclose tumor biology and drive improved diagnostics, treatment and management of cancer. To this end, we use label-free mass spectrometry-based proteomics that is optimally suited for large- ShT-39-2 scale clinical sample profiling. I will highlight our work in vari- Development of a diagnostic SARI test system ous cancer types with a focus on exosome proteomics for non- based on protein microchip for detection and invasive diagnostics and phosphoproteomics for response predic- tion. More specifically, I will discuss our prostate cancer effort forecasting the severity of acute respiratory that made use of an innovative workflow for high-throughput infections 1,2 1 1 1 extracellular vesicle proteomics applied to prostate cancer cell A. Taraskin , A. Lozhkov , M. Plotnikova , S. Klotchenko 1 lines and urinary patient samples. Furthermore I will highlight Smorodintsev Research Institute of Influenza, Saint-Petersburg, 2 our newly developed computational analysis approach for Inte- Russia, Peter the Great St. Petersburg Polytechnic University, grative inferred kinase activity (INKA) analysis that can rank Saint-Petersburg, Russia kinase activities in mass spectrometry-based phosphoproteome According to the World Health Organization (WHO), acute res- data derived from single samples. We show that INKA can piratory viral infections cause the overwhelming majority of all uncover oncogenes, differential kinase activity and drug targets. reported infectious diseases, yet methods for their molecular diag- We believe that cancer proteomics powered by precise measure- nosis are limited. The purpose of this study is to develop a multi- ments and dedicated analysis will realize the full potential of mul- parameter diagnostic assay, including a set of reagents, based on ti-parameter diagnostics and personalized medicine. protein microchip technology, which allows personalized diagno- sis of influenza-like illnesses and severe acute respiratory infec- tions (SARI). Ideally, such diagnostics will be capable of determining etiological agents and providing prognostic

FEBS Open Bio 9 (Suppl. 1) (2019) 2–64 DOI: 10.1002/2211-5463.12674 63 ª 2019 The Authors. FEBS Open Bio ª 2019 FEBS